Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2024 Nov 1;26(11):euae272.
doi: 10.1093/europace/euae272.

Drug therapy and catheter ablation for management of arrhythmias in continuous flow left ventricular assist device's patients: a Clinical Consensus Statement of the European Heart Rhythm Association and the Heart Failure Association of the ESC

Affiliations
Practice Guideline

Drug therapy and catheter ablation for management of arrhythmias in continuous flow left ventricular assist device's patients: a Clinical Consensus Statement of the European Heart Rhythm Association and the Heart Failure Association of the ESC

Petr Peichl et al. Europace. .

Erratum in

Abstract

Left ventricular assist devices (LVADs) are an increasingly used strategy for the management of patients with advanced heart failure. Although these devices effectively improve survival, atrial and ventricular arrhythmias are common with a prevalence of 20-50% at one year after LVAD implantation. Arrhythmias predispose these patients to additional risk and are associated with considerable morbidity from recurrent implantable cardioverter-defibrillator shocks, progressive failure of the unsupported right ventricle, and herald an increased risk of mortality. Management of patients with arrhythmias and LVAD differs in many aspects from the general population heart failure patients. These include ruling out the reversible causes of arrhythmias that in LVAD patients may include mechanical irritation from the inflow cannula and suction events. For patients with symptomatic arrhythmias refractory to medical treatment, catheter ablation might be relevant. There are specific technical and procedural challenges perceived to be unique to LVAD-related ventricular tachycardia (VT) ablation such as vascular and LV access, signal filtering, catheter manoeuvrability within decompressed chambers, and electroanatomic mapping system interference. In some patients, the arrhythmogenic substrate might not be readily accessible by catheter ablation after LVAD implantation. In this regard, the peri-implantation period offers a unique opportunity to surgically address arrhythmogenic substrate and suppress future VT recurrences. This document aims to address specific aspects of the management of arrhythmias in LVAD patients focusing on anti-arrhythmic drug therapy and ablations.

Keywords: Atrial fibrillation; Catheter ablation; Heart failure; Left ventricular assist device; Ventricular arrhythmia.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: O.A. serves as an advisor for Novartis, Boehringer Ingelheim, AstraZeneca, Merck Sharp & Dohme, Sanofi, Bayer, Pfizer, Amgen, Bristol Myers Squibb, Eli Lilly and reports consulting fees from Medical Consults: Restore -Medical, Cordio-Medical, and Boehringer Ingelheim. A.B-G. serves as an advisor for Abbott, AstraZeneca, Boehringer-Ingelheim, Bayer, Medtronic, Novartis, Roche Diagnostics, and Vifor. F.G. serves as an advisor for Abbott, FineHeart, AdjuCor, Corwave, Bayer, Astra-Zeneca, Ionis, Alnylam, and Roche. M.PE. reports research funding from Boehringer Ingelheim, Roche, SQ Innovations, Astra Zeneca, Novartis, Novo Nordisk, Medtronic, Boston Scientific, Pharmacosmos, and consultancy for Abott, Akero, Applied Therapeutics, Amgen, AnaCardio, Biosensors, Boehringer Ingelheim, Corteria, Novartis, Astra Zeneca, Novo Nordisk, Abbvie, Bayer, Horizon Therapeutics, Foundry, Takeda, Cardiorentis, Pharmacosmos, Siemens, Eli Lilly, Vifor, New Amsterdam, Moderna, Teikoku, LIB Therapeutics, 3R Lifesciences, Reprieve, FIRE 1, Corvia, Regeneron. M.PA. reports fees from Abbott Vascular, AstraZeneca, Boehringer Ingelheim, Novartis, Roche Diagnostics, and Vifor Pharma. P.P. reports speakers’ honoraria from Boston Scientific, Abbott, Medtronic, Biosense Webster, and Biotronik. F.S. reports speakers’ honoraria from Abbott, Biosense Webster, Boston Scientific, and Medtronic, and consulting fees from Inheart. Others report no relevant conflicts of interest.

Figures

Figure 1
Figure 1
Table of advice structure.
Figure 2
Figure 2
Management strategies for LVAD patients with recurrent VAs and ICD.
Figure 3
Figure 3
An example of an intra-aortic thrombus on a CT scan (arrow).
Figure 4
Figure 4
(A) CT scan of a patient with HeartMate 3 and ischaemic cardiomyopathy treated with dedicated software to be integrated into a 3D mapping system. (B) Integration of the images in the 3D mapping system with the bipolar voltage map.
Figure 5
Figure 5
ICE during VT ablation in an LVAD patient. (A) Normal-sized LV cavity with the ablation catheter close cannula. (B) Small ‘decompressed’ LV cavity due to unloading by LVAD.
Figure 6
Figure 6
An example of 12-lead ECGs recorded in a patient with HeartMate3 using conventional filter setting (A) and after adjusting the low-pass filter to 40 Hz (B).

Similar articles

Cited by

References

    1. Tomasoni D, Vishram-Nielsen JKK, Pagnesi M, Adamo M, Lombardi CM, Gustafsson F et al. Advanced heart failure: guideline-directed medical therapy, diuretics, inotropes, and palliative care. ESC Heart Fail 2022;9:1507–23. - PMC - PubMed
    1. Darma A, Arya A, Dagres N, Kühl M, Hindricks G, Eifert S et al. Validation of the VT-LVAD score for prediction of late VAs in LVAD recipients. J Cardiovasc Electrophysiol 2021;32:515–22. - PubMed
    1. Galand V, Flécher E, Auffret V, Boulé S, Vincentelli A, Dambrin C et al. Predictors and clinical impact of late ventricular arrhythmias in patients with continuous-flow left ventricular assist devices. JACC Clin Electrophysiol 2018;4:1166–75. - PubMed
    1. Hickey KT, Garan H, Mancini DM, Colombo PC, Naka Y, Sciacca RR et al. Atrial fibrillation in patients with left ventricular assist devices: incidence, predictors, and clinical outcomes. JACC Clin Electrophysiol 2016;2:793–8. - PubMed
    1. Efimova E, Fischer J, Bertagnolli L, Dinov B, Kircher S, Rolf S et al. Predictors of ventricular arrhythmia after left ventricular assist device implantation: a large single-center observational study. Heart Rhythm 2017;14:1812–9. - PubMed

Publication types

Substances